RhumbLine Advisers
KNSA icon

RhumbLine Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

RhumbLine Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351K Hold
7,286
– – ﹤0.01% 2822
2025
Q4 		$301K Hold
7,286
– – ﹤0.01% 2965
2025
Q3 		$283K Hold
7,286
– – ﹤0.01% 3034
2025
Q2 		$202K Sell
7,286
-55,414
-88% -$1.41M ﹤0.01% 3224
2025
Q1 		$1.39M Buy
62,700
+3,745
+6% +$77.1K ﹤0.01% 2011
2024
Q4 		$1.17M Sell
58,955
-909
-2% -$20.7K ﹤0.01% 2171
2024
Q3 		$1.5M Buy
59,864
+3,798
+7% +$92.5K ﹤0.01% 2052
2024
Q2 		$1.05M Sell
56,066
-5,365
-9% -$101K ﹤0.01% 2217
2024
Q1 		$1.21M Buy
61,431
+494
+0.8% +$9.65K ﹤0.01% 2145
2023
Q4 		$1.07M Sell
60,937
-2,196
-3% -$36.1K ﹤0.01% 2212
2023
Q3 		$1.1M Buy
63,133
+3,871
+7% +$65.2K ﹤0.01% 2151
2023
Q2 		$834K Buy
59,262
+13,171
+29% +$176K ﹤0.01% 2400
2023
Q1 		$496K Buy
46,091
+1,681
+4% +$22.1K ﹤0.01% 2434
2022
Q4 		$665K Buy
44,410
+1,427
+3% +$20.8K ﹤0.01% 2335
2022
Q3 		$552K Buy
42,983
+2,939
+7% +$33.5K ﹤0.01% 2449
2022
Q2 		$388K Buy
40,044
+4,650
+13% +$43.4K ﹤0.01% 2623
2022
Q1 		$352K Buy
35,394
+737
+2% +$7.81K ﹤0.01% 2583
2021
Q4 		$408K Sell
34,657
-812
-2% -$9.98K ﹤0.01% 2593
2021
Q3 		$404K Sell
35,469
-968
-3% -$12.6K ﹤0.01% 2638
2021
Q2 		$508K Buy
36,437
+7,675
+27% +$117K ﹤0.01% 2560
2021
Q1 		$532K Sell
28,762
-1,655
-5% -$33.9K ﹤0.01% 2469
2020
Q4 		$537K Buy
30,417
+4,711
+18% +$82.8K ﹤0.01% 2415
2020
Q3 		$394K Buy
25,706
+2,424
+10% +$45.5K ﹤0.01% 2397
2020
Q2 		$593K Buy
23,282
+6,375
+38% +$133K ﹤0.01% 2271
2020
Q1 		$262K Buy
16,907
+44
+0.3% +$688 ﹤0.01% 2465
2019
Q4 		$187K Buy
16,863
+335
+2% +$2.91K ﹤0.01% 2767
2019
Q3 		$141K Sell
16,528
-38
-0.2% -$420 ﹤0.01% 2826
2019
Q2 		$224K Buy
16,566
+3,755
+29% +$58.3K ﹤0.01% 2743
2019
Q1 		$231K Buy
12,811
+4,862
+61% +$93.9K ﹤0.01% 2682
2018
Q4 		$223K Buy
+7,949
New +$166K ﹤0.01% 2681

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RhumbLine Advisers's KNSA Position: Q1 2026 in Review

RhumbLine Advisers held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 7,286 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

RhumbLine Advisers first reported a position in KNSA in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.5M in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • RhumbLine Advisers held 7,286 shares of Kiniksa Pharmaceuticals worth $351K as of Q1 2026.
  • RhumbLine Advisers left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2822 holding.
  • RhumbLine Advisers first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 30 quarters since.
  • RhumbLine Advisers's Kiniksa Pharmaceuticals position peaked at $1.5M in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.